SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
-4.4%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$1.13B
AUM Growth
+$1.13B
(-0.41%)
Cap. Flow
+$24.4M
Cap. Flow
% of AUM
2.16%
Top 10 Holdings %
Top 10 Hldgs %
36.51%
Holding
116
New
25
Increased
31
Reduced
26
Closed
23
Top Buys
| 1 |
Terns Pharmaceuticals
TERN
|
$33.7M |
| 2 |
Iovance Biotherapeutics
IOVA
|
$32.4M |
| 3 |
Praxis Precision Medicines
PRAX
|
$20.5M |
| 4 |
Nurix Therapeutics
NRIX
|
$19.6M |
| 5 |
Enliven Therapeutics
ELVN
|
$18M |
Top Sells
| 1 |
Rigel Pharmaceuticals
RIGL
|
$67.4M |
| 2 |
Teva Pharmaceuticals
TEVA
|
$47.1M |
| 3 |
United Therapeutics
UTHR
|
$37.7M |
| 4 |
GeneDx Holdings
WGS
|
$18.2M |
| 5 |
HCA Healthcare
HCA
|
$17.2M |
Sector Composition
| 1 | Healthcare | 99.14% |
| 2 | Consumer Staples | 0.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Syndax Pharmaceuticals
SNDX
$1.41B
| $17M | 1.5% | 826,500 +457,500 | +124% | +$9.39M |
|
27
Humana
HUM
$36.5B
| $16.6M | 1.46% | 44,356 -27,650 | -38% | -$10.3M |
|
28
GSK
GSK
$79.9B
| $16M | 1.41% | 415,000 +95,783 | +30% | +$3.69M |
|
29
Treace Medical Concepts
TMCI
$464M
| $15.7M | 1.39% | 2,365,648 +1,020,000 | +76% | +$6.78M |
|
30
Vaxcyte
PCVX
$4B
| $14M | 1.23% | 185,250 -22,500 | -11% | -$1.7M |
|
31
10x Genomics
TXG
$1.74B
| $14M | 1.23% | +719,000 | New | +$14M |
|
32
CG Oncology
CGON
$2.04B
| $13.4M | 1.18% | 424,585 +206,714 | +95% | +$6.53M |
|
33
Nuvalent
NUVL
$5.52B
| $13M | 1.15% | 171,788 +42,500 | +33% | +$3.22M |
|
34
Evolus
EOLS
$494M
| $12.5M | 1.1% | 1,152,000 +992,000 | +620% | +$10.8M |
|
35
Enanta Pharmaceuticals
ENTA
$180M
| $10.4M | 0.91% | 799,546 +219,000 | +38% | +$2.84M |
|
36
Alector
ALEC
$238M
| $10.2M | 0.9% | +2,239,006 | New | +$10.2M |
|
37
Keros Therapeutics
KROS
$618M
| $10.1M | 0.89% | 221,600 -52,000 | -19% | -$2.38M |
|
|
38
Teva Pharmaceuticals
TEVA
$21.1B
| $9.53M | 0.84% | 586,499 -2,899,941 | -83% | -$47.1M |
|
39
Arcellx
ACLX
$3.85B
| $9.42M | 0.83% | 170,741 +20,741 | +14% | +$1.14M |
|
40
Biodesix
BDSX
$62.6M
| $9.35M | 0.82% | +6,111,964 | New | +$9.35M |
|
41
Tango Therapeutics
TNGX
$747M
| $9.01M | 0.79% | 1,049,895 -300,250 | -22% | -$2.58M |
|
42
OrthoPediatrics
KIDS
$536M
| $8.9M | 0.79% | +309,500 | New | +$8.9M |
|
|
43
Rigel Pharmaceuticals
RIGL
$697M
| $8.58M | 0.76% | 1,043,697 -8,198,289 | -89% | -$67.4M |
|
44
Bausch Health
BHC
$2.74B
| $8.41M | 0.74% | 1,206,000 +536,000 | +80% | +$3.74M |
|
45
Immunic
IMUX
$80.9M
| $8.1M | 0.71% | 7,293,007 | – | – |
|
46
Y-mAbs Therapeutics
YMAB
$388M
| $7.83M | 0.69% | 647,982 +77,000 | +13% | +$930K |
|
47
enGene Holdings
ENGN
$236M
| $7.54M | 0.67% | 800,000 | – | – |
|
48
Pharvaris
PHVS
$1.39B
| $7.51M | 0.66% | 399,430 -2,471 | -0.6% | -$46.5K |
|
|
AVDL
49
Avadel Pharmaceuticals
AVDL
$1.43B
| $7.16M | 0.63% | +509,000 | New | +$7.16M |
|
50
Dyne Therapeutics
DYN
$1.92B
| $7.09M | 0.63% | +201,000 | New | +$7.09M |
|